Please note that to receive credit you must achieve a score of at least 80%.
Credit will be uploaded to CPE Monitor within 4 weeks of successful completion of the activity.

Post-Activity Test

Question Title

1. The therapeutic target of epoprostenal is within the:

Question Title

2. Treprostinil is available in all of the following formulations except:

Question Title

3. The use of nitrates is contraindicated in patients receiving a phosphodiesterase type 5 (PDE-5) inhibitor.

Question Title

4. Pulmonary arterial hypertension is defined as having a mean pulmonary arterial pressure (mPAP) of:

Question Title

5. Current PAH therapy targets all of the following pathways except:

T